Aragen Life Sciences files DRHP for ₹800 cr fresh issue
Aragen Life Sciences has filed a Draft Red Herring Prospectus with SEBI for an IPO consisting of an ₹800 crore fresh issue and an offer for sale. The company intends to use the proceeds to repay debt and fund capital expenditure at its Hyderabad and Bengaluru facilities.
Why it matters
The IPO reflects ongoing growth and capital-raising activities within India's pharmaceutical and contract research sector.
Contract research, development and manufacturing organisation (CRDMO) Aragen Life Sciences has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) for an initial public offering (IPO).
The article is a factual report on a corporate financial filing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in